Eli Lilly shares hit all-time high above $1,400 on stronger-than-expected Q3 earnings

Eli Lilly made new all-time highs above $1,400 on stronger-than-expected Q3 2026 earnings, with traders injecting more capital into the stock. The company's Mounjaro and Zepbound weight-loss and diabetes treatments drove revenue.

Detected & updated continuously · Source: Nebula